Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris (MEDCOR)

September 25, 2014 updated by: Therabel Pharma SA/NV

Double-blind Parallel Placebo-controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients With Stable Angina Pectoris Undergoing a Percutaneous Coronary Intervention

Molsidomine used as an add-on treatment on standard care therapy should be superior to placebo used also as an add-on treatment on standard care therapy on improving the endothelial function (endothelium score measured by reactive hyperemia - peripheral arterial tonometry [RH-PAT]) after 12 months of treatment in patients with stable angina patients and undergoing elective percutaneous coronary intervention.

The study will be double-blind, parallel-group, randomised, multicentre, sequential, placebo-controlled study.

The device used to determine RH-PAT will be EndoPAT. Duration of the treatment = one year.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A Data Steering Committee (DSC) will blindly assess the recruitment rate, the variability of RH-PAT within and between centres, and the safety on a regular basis.

Sequential approach:

  • In the first phase (Phase A) of the study, 180 patients will be enrolled in order to get at least 50 completers after 12 months of treatment. A statistical evaluation of the primary endpoint will be done by an Independent Biostatistician after approximately 50 patients have completed the study in accordance with the protocol.

  • The results will be examined by an Independent Data Monitoring Committee (IDMC)which will assess the results and advise the sponsor as to:

    1. Continue the study if the primary objective has not been achieved but the difference between the two groups is at least 10% (difference considered clinically significant). In this case, the sample size will be recalculated by the Independent Biostatistician taking into account actual difference and variability. The total number of patients to be enrolled in addition in Phase B will be calculated with precision. Depending on IDMC recommendations, the number of investigating centres will be increased or not for Phase B. If the right number of patients has already been enrolled, Phase B will not start. The study will stop when all enrolled patients have completed the one-year treatment period.
    2. Terminate the study, if the difference between the two groups is less than 10%.
    3. Consider the study as completed if the primary endpoint has been achieved.

Treatment allocation: Balanced allocation between molsidomine and placebo (1:1) with a stratification for consumption of statins, for the type of stent (drug-eluting stent or bare-metal) and for consumption of angiotensin-converting enzyme inhibitors (ACEIs).

Data collection: Electronic Case Report Form (eCRF).

Duration of study: A minimum of 30 months (16 months for inclusion and 14 months for the study) for Phase A.

Number of investigational centres:

  • Up to 10 centres for Phase A
  • To be determined for Phase B based on Phase A.

Study Type

Interventional

Enrollment (Actual)

165

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Aalst, Belgium, 9300
        • Onze Lieve Vrouw Ziekenhuis

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged at least 18 years.
  • No treatment with molsidomine and/or long-acting nitrates (oral or patches) for more than 48 hours during the month preceding percutaneous coronary intervention (PCI) and no treatment with these same drugs within 3 days before PCI.
  • Patients who the investigator believes that they and/or their Legally Acceptable Representative (LAR) can and will comply with the requirements of the protocol.
  • Written informed consent from the patient or from the LAR.
  • Patients who underwent PCI for stable angina pectoris one month prior to the start of the study.
  • Patients presenting endothelial dysfunction at Month 0 (score of the Endo-PAT <0.40).

Exclusion Criteria:

  • Pre-menopausal women.
  • Patient with a clinically-active malignancy.
  • Known major renal insufficiency or known significant hepatic insufficiency.
  • History of psychological disorder, mental dysfunction, alcohol or drug abuse or any other factor which might interfere with the ability to cooperate in the study.
  • Participation in another clinical trial which has not yet reached its primary endpoint or with the same primary endpoint during the previous month.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject will be exposed to an investigational or a non-investigational product (vaccine, drug or device).
  • Hypersensitivity to molsidomine or to one of its excipients.
  • Peri-procedural infarction: creatine kinase-muscle/brain (CK-MB) >3 times the upper reference limit.
  • Clinically significant abnormal pre-PCI CK-MB and troponin: any elevation above the upper reference limit.
  • Intolerance to galactose, deficiency in Lapp lactase or glucose-galactose malabsorption.
  • Left ventricular insufficiency (New York Heart Association [NYHA] class III or IV) with an ejection fraction <35%.
  • Acute circulatory insufficiency (e.g. cardiogenic shock).
  • Hypotension: systolic blood pressure <100 mmHg and/or diastolic blood pressure <70 mmHg.
  • Atrial fibrillation
  • Acute myocardial infarction during the preceding month.
  • Unsuccessful PCI: residual stenosis of at least 50%.
  • Patient taking phosphodiesterase-5 inhibitors, such as sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil (Cialis®)
  • Patient taking nebivolol (Nobiten®)
  • Patient taking ibuprofen + L-arginine as excipient (Spidifen®)
  • Patient meeting any contraindication(s) from Coruno®. Please refer to Coruno® (molsidomine 16 mg o.d.)Summary of Product Characteristics (SPC).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Molsidomine
Coruno (molsidomine 16 mg tablet; per os; once daily)
Drug: Coruno
Molsidomine 16 mg tablet, per os, once a day
Other Names:
  • Molsidomine
PLACEBO_COMPARATOR: Placebo
Placebo (16 mg tablet; once a day)
Drug: Placebo
Placebo (16 mg tablet, per os; once-daily)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change Versus Baseline in the Score of the EndoPAT in the Two Groups After One Year of Treatment (Month 12).
Time Frame: 12 months
The results are expressed mean relative change (%) between month 12 and baseline. A positive result means improvement in the score of the EndoPAT between baseline and month 12. It could be considered as a surrogate of a decrease of the endothelial dysfunction. A negative percentage means the inverse. The are no fixed limits to the scale. The minimum observed was -275% and the maximum observed was +4200%.
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change Versus Baseline in the Score of the EndoPAT in the Two Groups After Six Months of Treatment (Month 6).
Time Frame: Month 6
The results are expressed mean relative change (%) between month 6 and baseline. A positive result means improvement in the score of the EndoPAT between baseline and month 6. It could be considered as a surrogate of a decrease of the endothelial dysfunction. A negative percentage means the inverse. The are no fixed limits to the scale. The minimum observed was -200% and the maximum observed was +6100%.
Month 6
Change Versus Baseline in the Augmentation Index in the Two Groups After Six and Twelve Months of Treatment (Months 6 and 12).
Time Frame: Month 6 and Month 12
The results are expressed mean relative change (%) between month 6 or month 12, and baseline. A positive result means improvement in the augmentation index between baseline and month 6 or month 12. It could be considered as a surrogate of a decrease of the arterial stiffness. A negative percentage means the inverse. The are no fixed limits to the scale. At month 6,the minimum observed was -139% and the maximum observed was +1600%.At month 12, the minimum observed was -524% and the maximum observed was +1600%.
Month 6 and Month 12
Change Versus Baseline in Some Specific Endothelial Biomarkers After Twelve Months of Treatment (Month 12).
Time Frame: Month 12
Month 12
Frequency of Serious Cardiovascular Events (SCEs) in the Two Groups After Twelve Months of Treatment (Month 12).
Time Frame: Month 12
Sum of the events collected during 12 months.
Month 12
Frequency of AEs and SAEs in the Two Groups After Twelve Months of Treatment (Month 12).
Time Frame: Month 12
Sum of the events collected during 12 months.
Month 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Therabel Pharma SA/NV

Investigators

  • Principal Investigator: Emanuele Barbato, MD, Cardiology Center, Onze Lieve Vrouw Ziekenhuis Aalst

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2011

Primary Completion (ACTUAL)

September 1, 2014

Study Completion (ACTUAL)

September 1, 2014

Study Registration Dates

First Submitted

April 1, 2011

First Submitted That Met QC Criteria

May 29, 2011

First Posted (ESTIMATE)

June 1, 2011

Study Record Updates

Last Update Posted (ESTIMATE)

October 6, 2014

Last Update Submitted That Met QC Criteria

September 25, 2014

Last Verified

September 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MEDCOR 2011
  • 2011-000190-31 (EUDRACT_NUMBER)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atherosclerosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe